

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2005 年 9 月 29 日 (29.09.2005)

PCT

(10) 国際公開番号
WO 2005/090405 A1

(51) 国際特許分類: C07K 16/28, A61K 39/395,
A61P 1/04, 1/18, 13/12, 17/06, 19/02, 29/00, 31/04, 31/18,
35/00, 37/02, 37/06 // C12N 15/09, C12P 21/08

(74) 代理人: 青木 篤, 外(AOKI, Atsushi et al.); 〒1058423
東京都港区虎ノ門三丁目5番1号 虎ノ門37森ビ
ル 青和特許法律事務所 Tokyo (JP).

(21) 国際出願番号: PCT/JP2005/006229

(81) 指定国 (表示のない限り、全ての種類の国内保護が
可能): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) 国際出願日: 2005 年 3 月 24 日 (24.03.2005)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:
特願2004-087578 2004 年 3 月 24 日 (24.03.2004) JP

(84) 指定国 (表示のない限り、全ての種類の広域保護
が可能): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR),
OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG).

(71) 出願人 (米国を除く全ての指定国について): 中
外製薬株式会社 (CHUGAI SEIYAKU KABUSHIKI
KAISHA) [JP/JP]; 〒1158543 東京都北区浮間5丁目
5番1号 Tokyo (JP).

(72) 発明者; および

(75) 発明者/出願人 (米国についてのみ): 加野勝宏 (KANO,
Katsuhiko) [JP/JP]; 〒1158543 東京都北区浮間5丁目
5番1号 中外製薬株式会社内 Tokyo (JP). 寺島 勇
(TERASHIMA, Isamu) [JP/JP]; 〒1158543 東京都北区
浮間5丁目5番1号 中外製薬株式会社内 Tokyo (JP).

添付公開書類:
— 国際調査報告書

2文字コード及び他の略語については、定期発行される
各PCTガゼットの巻頭に掲載されている「コードと略語
のガイダンスノート」を参照。

(54) Title: SUBTYPE OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR

(54) 発明の名称: インターロイキン-6受容体に対するヒト型化抗体のサブタイプ

(57) Abstract: As a subtype of humanized PM-1 antibody against interleukin-6 receptor (IL-6R), there is provided antibody sub-
type (1) whose one heavy chain C terminus consists of Pro-NH₂ (447). As another subtype of humanized PM-1 antibody against
interleukin-6 receptor (IL-6R), there is provided antibody subtype (2) whose both heavy chain C termini consist of Pro-NH₂ (447).
Furthermore, there are provided pharmaceutical compositions comprising these.

(57) 要約: インターロイキン-6受容体 (IL-6R) に対するヒト型化PM-1抗体のサブタイプであって、片方の重鎖C
末端がPro-NH₂ (447) である抗体サブタイプ (1)、及びインターロイキン-6受容体 (IL-6R) に対するヒト型化
PM-1抗体のサブタイプであって、両方の重鎖C末端がPro-NH₂ (447) である抗体サブタイプ (2)、並びにこれら
を含んで成る医薬組成物。



WO 2005/090405 A1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/006229

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.⁷ C07K16/28, A61K39/395, A61P1/04, 1/18, 13/12, 17/06, 19/02,
29/00, 31/04, 31/18, 35/00, 37/02, 37/06//C12N15/09, C12P21/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl.⁷ C07K16/28, A61K39/395, A61P1/04, 1/18, 13/12, 17/06, 19/02,
29/00, 31/04, 31/18, 35/00, 37/02, 37/06//C12N15/09, C12P21/08

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2005
Kokai Jitsuyo Shinan Koho 1971-2005 Toroku Jitsuyo Shinan Koho 1994-2005

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI (DIALOG), BIOSIS (DIALOG), JICST FILE (JOIS)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JP 05-227970 A (Chugai Pharmaceutical Co., Ltd.), 07 September, 1993 (07.09.93), Par. Nos. [0140] to [0143], [0170] to [0171] & WO 1992/019759 A1 Page 64, line 3 to page 65, line 15; example 10 & US 5795965 A1 & EP 0628639 A1	1-6
Y	JP 2002-510211 A (Genentech, Inc.), 02 April, 2002 (02.04.02), Page 77, line 14 to page 79, line 10 & WO 1999/001556 A2 & US 5994511 A1	1-6



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search
19 May, 2005 (19.05.05)

Date of mailing of the international search report
07 June, 2005 (07.06.05)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/006229

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MERKLER et al., Recombinant type A rat 75-kDa alpha-amidating enzyme catalyzes the conversion of glycine-extended peptides to peptide amides via an alpha-hydroxyglycine intermediate, Arch.Biochem.Biophys., Vol.289, No.1, 15 August, 1991 (15.08.91), pages 192 to 196	1-6
Y	MILLER et al., Characterization of a bifunctional peptidylglycine alpha-amidating enzyme expressed in Chinese hamster ovary cells, Arch.Biochem.Biophys., Vol.298, No.2, 01 November, 1992 (01.11.92), pages 380 to 388	1-6
Y	RAY et al., Production of salmon calcitonin by direct expression of a glycine-extended precursor in Escherichia coli, Protein Expr. Purif., Vol.26, No.2, 2002.11, pages 249 to 259	1-6
Y	JP 2002-525104 A (SmithKline Beecham Corp.), 13 August, 2002 (13.08.02), Par. No. [0123] & WO 2000/018804 A1 & US 6365154 B1	1-6
Y	JP 06-319396 A (Japan Tobacco Inc.), 22 November, 1994 (22.11.94), Par. No. [0028] (Family: none)	1-6
Y	ADAMCZYK et al., Complete sequencing of anti-vancomycin fab fragment by liquid chromatography-electrospray ion trap mass spectrometry with a combination of database searching and manual interpretation of the MS/MS spectra, J.Immunol.Methods, Vol.260, No.1-2, 01 February, 2002 (01.02.02), pages 235 to 249	1-6
A	HIRATA et al., Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies, J.Immunol., Vol.143, No.9, 01 November, 1989 (01.11.89), pages 2900 to 2906	1-6